(R) -5- [3-Chloro-4- (2,3-dihydroxy-propoxy) -benc [Z] iliden] -2 - ([Z] -propylimino) -3-o-tolyl-thiazolidin-4- one (Compound 1), or a pharmaceutically acceptable salt thereof, for use in the treatment and / or prevention of diseases or disorders selected from the group consisting of rejection of transplanted organs, graft versus host diseases caused by the transplant of stem cells, autoimmune syndromes selected from rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases selected from Crohn's disease and ulcerative colitis, psoriasis, psoriatic arthritis, Hashimoto's thyroiditis and uveo-retinitis, selected atopic diseases of rhinitis, conjunctivitis and dermatitis, asthma, type I diabetes, post-infectious autoimmune diseases selected from rheumatic fever and post-infectious glomerulonephritis, solid cancers and tumor metastases, in which Compound 1 or a pharmaceutically acceptable salt thereof or to be administered orally to a human subject in such a way that during the initial treatment phase Compound 1 has to be administered at an initial dose that is between 2 and 5 times lower than the target dose, until no reduction of acute heart rate, in which reduction in acute heart rate refers to a decrease in heart rate of pre-dose values of 10 or more beats per minute (bpm) that are maximum in 1-3 hours after drug administration, followed by ascending dose titration to the target dose, in which the target dose is 20 or 40 mg of Compound 1 to be administered orally once daily, in which the dose below the target dose should be administered at a dosage frequency of once or twice a day and in which titration ascending to the target dose should be performed in one or several dose increases.(R)-5-[3-cloro-4-(2,3-dihidroxi-propoxi)-benc[Z]iliden]-2-([Z]-propilimino)-3-o-tolil-tiazolidin-4-ona (Compuesto 1), o una sal farmacéuticamente aceptable del mismo, para su uso en el tratamiento y/o la prevención de enfermedades o trastornos seleccionados del grupo que co
